Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H7XL
|
|||
| Former ID |
DCL001095
|
|||
| Drug Name |
OSI-027
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Phase 2 | [1] | |
| Company |
OSI
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22N6O3
|
|||
| Canonical SMILES |
COC1=CC=CC2=C1NC(=C2)C3=C4C(=NC=NN4C(=N3)C5CCC(CC5)C(=O)O)N
|
|||
| InChI |
1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24)
|
|||
| InChIKey |
JROFGZPOBKIAEW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 936890-98-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:91363
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011 Aug;10(8):1394-406. | |||
| REF 2 | Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.